The role of the ubiquitin proteasome system in lymphoma.

作者: K. Stephen Suh , Takemi Tanaka , Sreeja Sarojini , Ginah Nightingale , Rajendra Gharbaran

DOI: 10.1016/J.CRITREVONC.2013.02.005

关键词:

摘要: The ubiquitin-proteasome system (UPS) maintains the integrity of cellular processes by controlling protein degradation pathways. role UPS in proliferation, cell cycle, differentiation, DNA repair, folding, and apoptosis is well documented, a wide range activities these signaling pathways can be manipulated inhibitors, which include many anti-cancer agents. Naturally occurring synthetic drugs designed to target are currently used for hematological cancers, including lymphoma. These largely interfere with E1 E2 regions 26S proteasome, blocking proteasomal activity promoting enhancing extrinsic (death receptors, Trail, Fas) intrinsic (caspases, Bax, Bcl2, p53, nuclear factor-kappa B, p27) death programs. This review focuses on recent clinical developments concerning that affected down-regulation activities, apoptotic mechanisms promoted this class treat

参考文章(158)
Morton Coleman, John P. Leonard, Richard R. Furman, Peter Martin, Jia Ruan, Ying-Kuen K. Cheung, Julie M. Vose, Ann S. LaCasce, Rebecca Elstrom, Phase 1 trial of bortezomib plus R‐CHOP in previously untreated patients with aggressive non‐Hodgkin lymphoma Cancer. ,vol. 116, pp. 5432- 5439 ,(2010) , 10.1002/CNCR.25509
Alessio Nencioni, Lucia Wille, Giovanna Dal Bello, Davide Boy, Gabriella Cirmena, Sebastian Wesselborg, Claus Belka, Peter Brossart, Franco Patrone, Alberto Ballestrero, Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clinical Cancer Research. ,vol. 11, pp. 4259- 4265 ,(2005) , 10.1158/1078-0432.CCR-04-2496
Nancy B. Davis, David A. Taber, Rafat H. Ansari, Christopher W. Ryan, Christopher George, Everett E. Vokes, Nicholas J. Vogelzang, Walter M. Stadler, Phase II Trial of PS-341 in Patients With Renal Cell Cancer: A University of Chicago Phase II Consortium Study Journal of Clinical Oncology. ,vol. 22, pp. 115- 119 ,(2004) , 10.1200/JCO.2004.07.165
Owen A. O'Connor, John Wright, Craig Moskowitz, Jamie Muzzy, Barbara MacGregor-Cortelli, Michael Stubblefield, David Straus, Carol Portlock, Paul Hamlin, Elizabeth Choi, Otila Dumetrescu, Dixie Esseltine, Elizabeth Trehu, Julian Adams, David Schenkein, Andrew D. Zelenetz, Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma Journal of Clinical Oncology. ,vol. 23, pp. 676- 684 ,(2005) , 10.1200/JCO.2005.02.050
Amanda F. Cashen, Nancy L. Bartlett, Therapy of relapsed Hodgkin lymphoma. Blood Reviews. ,vol. 21, pp. 233- 243 ,(2007) , 10.1016/J.BLRE.2007.06.001
Joana Loureiro, Hidde L. Ploegh, Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions. Advances in Immunology. ,vol. 92, pp. 225- 305 ,(2006) , 10.1016/S0065-2776(06)92006-9
S. C. W. Ling, E. K. K. Lau, A. Al-Shabeeb, A. Nikolic, A. Catalano, H. Iland, N. Horvath, P. J. Ho, S. Harrison, S. Fleming, D. E. Joshua, J. D. Allen, Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1 Haematologica. ,vol. 97, pp. 64- 72 ,(2012) , 10.3324/HAEMATOL.2011.043331
Ravi K. Amaravadi, Duonan Yu, Julian J. Lum, Thi Bui, Maria A. Christophorou, Gerard I. Evan, Andrei Thomas-Tikhonenko, Craig B. Thompson, Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma Journal of Clinical Investigation. ,vol. 117, pp. 326- 336 ,(2007) , 10.1172/JCI28833
S. Jagannath, B. Barlogie, J. Berenson, D. Siegel, D. Irwin, P. G. Richardson, R. Niesvizky, R. Alexanian, S. A. Limentani, M. Alsina, J. Adams, M. Kauffman, D.-L. Esseltine, D. P. Schenkein, K. C. Anderson, A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma British Journal of Haematology. ,vol. 127, pp. 165- 172 ,(2004) , 10.1111/J.1365-2141.2004.05188.X